CLINICAL TRIALS AND OBSERVATIONS Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
نویسندگان
چکیده
1Department of Nuclear Medicine, University of Cologne, Cologne, Germany; 2German Hodgkin Study Group, University of Cologne, Cologne, Germany; 3Department of Clinical Hematology, Third Faculty of Medicine, Charles University, Prague, Czech Republic; 4Schweizer Arbeitsgruppe für Klinische Krebsforschung, Bern, Switzerland; 5Klinik für Strahlenheilkunde, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany; 6Department of Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 7Department of Nuclear Medicine, Hanover University Medical School, Hanover, Germany; 8Department of Hematology, VU University Medical Centre, Amsterdam, The Netherlands; 9Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany; 10Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany; 11Department of Nuclear Medicine, University of Wuerzburg, Wuerzburg, Germany; 12Department of Nuclear Medicine, Gutenberg University Hospital, Mainz, Germany; 13Department of Nuclear Medicine, University of Tuebingen, Tuebingen, Germany; 14Department of Radiation Oncology, University of Cologne, Cologne, Germany; and 15Department I of Internal Medicine, University of Cologne, Cologne, Germany
منابع مشابه
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Whole-Body Positron Emission Tomography Using 18F-Fluorodeoxyglucose for Posttreatment Evaluation in Hodgkin’s Disease and Non-Hodgkin’s Lymphoma Has Higher Diagnostic and Prognostic Value Than Classical Computed Tomography Scan Imaging
A residual mass after treatment of lymphoma is a clinical challenge, because it may represent vital tumor as well as tissue fibrosis. Metabolic imaging by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) offers the advantage of functional tissue characterization that is largely independent of morphologic criteria. We compared 18F-FDG PET to computed tomography (CT) in the pos...
متن کاملCLINICAL TRIALS AND OBSERVATIONS FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
Risk-adapted lymphoma treatment requires early and accurate assessment of prognosis. This investigation prospectively assessed the value of positron emission tomography with 2-[18F]fluoro-2-deoxy-Dglucose (FDG-PET) after two cycles of chemotherapy for prediction of progressionfree survival (PFS) and overall survival (OS) in Hodgkin lymphoma (HL). Seventy-seven consecutive, newly diagnosed patie...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma
This study was set up to demonstrate whether prognostic classification based on the secondary age-adjusted International Prognostic Index (sAA-IPI) for recurring aggressive non-Hodgkin lymphoma (NHL) or the prognostic score for recurring Hodgkin lymphoma (HL) can be improved by including the midtreatment results of fluorine-18-fluorodeoxy-glucose–positron emission tomography (FDG-PET). Clinical...
متن کاملInterim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift?
Hodgkin lymphoma (HL) is a curable disease with currently available chemotherapy regimens. Major late morbidities can potentially be avoided in most limited-stage HL patients if the treatment can be adapted to the patient's early response profile. The therapy efficacy can also be increased early during therapy in nonresponding HL patients with the addition of involved-field radiation therapy or...
متن کاملCLINICAL TRIALS AND OBSERVATIONS The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma
This is a phase 2 study to assess the role of tumor histogenesis (subtype), fluorodeoxyglucose positron emission tomography (FDG-PET), and short-course etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with dosedense rituximab (SC-EPOCH-RR) in newly diagnosed HIV-associated CD20 diffuse large B-cell lymphoma. Patients received a minimum of 3 and a maximum of 6 cycles with 1 ...
متن کامل